Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population

View Full Paper
Ask AI
Bookmark
Share

Authors

PHPaul J. HampelAKAmber B. KoehlerTHTalal Hilal

Discussion

Loading...

Member takes

Overview

Observational study reports overall survival and event-free survival in chronic lymphocytic leukemia, suggesting venetoclax-obinutuzumab is well-tolerated.

Key Points

  • The study aims to evaluate the efficacy and safety of venetoclax-obinutuzumab in treating chronic lymphocytic leukemia in frontline and relapsed settings.
  • Utilized the Mayo Clinic CLL Database to identify patients treated with venetoclax-obinutuzumab
  • Calculated overall survival and event-free survival with Kaplan-Meier methods
  • Compared survival rates to age- and sex-matched general population
  • A total of 154 patients included, with 68% male and a median age of 68
  • 1-, 3-, and 5-year event-free survival estimates were 91%, 85%, and 67% respectively
  • No significant difference in overall survival compared to the general population was observed.

Cite This Study

Hampel et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1b2https://doi.org/10.1182/blood-2025-3905
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions2025
  2. 2Real‐world comparative effectiveness of venetoclax‐obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia2024 · 9 citations
  3. 3Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial2026 · 1 citations
  4. 4Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia2026
  5. 5Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult leukemia group2025 · 3 citations